New pre-pandemic influenza vaccines: An egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice

Academic Article

Abstract

  • Highly pathogenic avian H5N1 influenza viruses that are currently circulating in southeast Asia may acquire the potential to cause the next influenza pandemic. A number of alternate approaches are being pursued to generate cross-protective, dose-sparing, safe, and effective vaccines, as traditional vaccine approaches, i.e., embryonated egg-grown, are not immunogenic. We developed a replication-incompetent adenoviral vector-based, adjuvant- and egg-independent pandemic influenza vaccine strategy as a potential alternative to conventional egg-derived vaccines. In this paper, we address suboptimal dose and longevity of vaccine-induced protective immunity and demonstrate that a vaccine dose as little as 1 × 106 plaque-forming unit (PFU) is sufficient to induce protective immune responses against a highly pathogenic H5N1 virus. Furthermore, the vaccine-induced humoral and cellular immune responses and protective immunity persisted at least for a year. © 2007 American Society for Clinical Pharmacology and Therapeutics.
  • Authors

    Digital Object Identifier (doi)

    Pubmed Id

  • 16902061
  • Author List

  • Hoelscher MA; Jayashankar L; Garg S; Veguilla V; Lu X; Singh N; Katz JM; Mittal SK; Sambhara S
  • Start Page

  • 665
  • End Page

  • 671
  • Volume

  • 82
  • Issue

  • 6